SurfWax News Index  |  Track News  |  Save/Exchange Information |  About Us

    News and Articles on Idiopathic thrombocytopenic purpura



    FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder  Nov 21, 2008
    Feudjo-Tepie M, Robinson N, Bennett D. Prevalence estimates of adult chronic idiopathic thrombocytopenic purpura (ITP). J Thromb Haemost. (PR Newswire)

    New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients  Nov 2, 2008
    Serious adverse events in hepatitis C trials included neuropsychiatric disorders (homicidal ideation, suicidal ideation, suicide attempt, suicide, psychotic disorder and hallucinations), serious and severe bacterial infections (sepsis), bone marrow toxicity (cytopenia and rarely, aplastic anemia), cardiovascular disorders (hypertension, supraventricular arrhythmias and myocardial infarction), hypersensitivity (including anaphylaxis), endocrine disorders (including thyroid disorders and diabetes... (PR Newswire)

    GSK Update on FDA Review of Promacta(R) (Eltrombopag)  Jun 21, 2008
    June 20 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: ) today announced that the United States Food and Drug Administration has extended the priority review period for PROMACTA(R) (eltrombopag) for the short-term treatment of previously treated patients with chronic idiopathic thrombocytopenic purpura, as they require more time to review the application ... On May 30, the Oncology Drugs Advisory Committee unanimously voted, 16-0, that eltrombopag demonstrated a favorable risk-benefit profile... (PR Newswire)

    FDA panel favors Glaxo, Ligand blood drug  May 31, 2008
    British drugmaker Glaxo and partner Ligand want Promacta approved to treat patients' with chronic idiopathic thrombocytopenic purpura, which causes excessive bruising and bleeding. About 60,000 people in the U.S. have the disease, according to Glaxo. (USA Today)

    FDA says Glaxo drug fails to control bleeding  May 30, 2008
    About 60,000 people in the U.S. have chronic idiopathic thrombocytopenic purpura, an immune system disorder that causes the body to destroy its own platelets, components of blood that help with clotting. In worst-case scenarios, the condition can cause fatal hemorrhaging in the brain. (San Diego Union-Tribune -- Business)

    Doctor 'Pay-for-performance' Improves Patient Care, Study Shows  Jan 12, 2008
    20, 2007) Physicians who treat a blood disorder called idiopathic thrombocytopenic purpura, characterized by easy bruising and excessive bleeding, now have a new tool to help them provide the best care for. (Nov. (Science Daily)

    GlaxoSmithKline seeks OK for Promacta bleeding disorder drug  Dec 21, 2007
    Promacta is an oral platelet growth factor therapy being developed to treat chronic idiopathic thrombocytopenic purpura, or ITP.. ITP is a rare disorder characterized by increased platelet destruction or inadequate platelet production in the blood, which causes an increased risk of bruising and bleeding. (Philadelphia Business Journal, PA)

    Glaxo files for FDA approval on potential blockbuster drug  Dec 21, 2007
    Promacta, known generically as eltrombopag, is a treatment for chronic idiopathic thrombocytopenic purpura. Patients with the condition do not create enough platelets in the blood, leading to a lack of clotting and an increased risk of bruising and bleeding. (Raleigh Triangle Business Journal, NC)

    Ligand Presents Positive LGD-4665 Phase I Clinical Trial Results at the American Society of Hematology Annual Meeting (ASH)  Dec 9, 2007
    Based on its strong potency, convenience and potential for dosing flexibility, we believe that LGD-4665 could be used as treatment for a wide variety of diseases associated with thrombocytopenia, including hepatitis C, chemotherapy-induced thrombocytopenia (CIT), myelodysplastic syndromes (MDS), idiopathic thrombocytopenic purpura (ITP) and several other cancers and liver diseases. LGD-4665 Study Design. (BusinessWire)

    Pivotal Phase 3 Romiplostim Study in Splenectomized Patients Meets Primary Endpoints  Dec 9, 2007
    Data Show Romiplostim Increased and Sustained Platelet Counts in Splenectomized Adult Patients with Immune Thrombocytopenic Purpura. ATLANTA--()--Amgen Inc. (NASDAQ:AMGN) today announced results from a randomized, pivotal Phase 3 study that showed romiplostim (AMG 531) increased and sustained platelet counts in splenectomized (spleen removed) adult patients with chronic Immune Thrombocytopenic Purpura (ITP). (BusinessWire)

    Drug May Help Reverse Clotting Deficiency  Nov 30, 2007
    The new drug is called eltrombopag, and in one study, patients with the autoimmune disorder idiopathic thrombocytopenic purpura (ITP) were able to use the medication to boost their platelet levels and cut their risk for bleeding. In a second study, patients with hepatitis C (HCV)-related cirrhosis of the liver were able to begin antiviral therapy for their condition after eltrombopag raised their platelet counts. (MEDLINEplus)

    Immune Thrombocytopenic Purpura — From Agony to Agonist  Nov 29, 2007
    In the summer of 1950, two hematology fellows working at the Barnes Hospital in St. Louis William J. Harrington and James W. Hollingsworth hatched a plan to test their idea that the cause of the idiopathic thrombocytopenic purpura (ITP) in a woman under their care was a factor in the blood that destroyed platelets. They decided that of the two fellows, the one whose blood type matched the patient's would receive 500 ml of her blood. (New England Journal of Medicine)

    Eltrombopag studied in Idiopathic Thrombocytopenic Purpura  Nov 29, 2007
    Public release date: 28-Nov-2007. Contact: Andrew Klein. (EurekAlert!)

    MS drug called effective, with checks for side effect  Oct 15, 2007
    Six patients in the trial were diagnosed with idiopathic thrombocytopenic purpura, characterized by a decline in platelet counts that can lead to potentially catastrophic internal bleeding. One patient died, four were successfully treated, and one recovered without treatment. (Boston Globe)

    Fairfield County scene: Golfing for a cure  Aug 7, 2007
    Triathlon Darien Sport Shop and the Idiopathic Thrombocytopenic Purpura Foundation of Darien present the third annual triathlon to raise funds for ITP research. Triathlons will be held in Darien and New Canaan; see Web site for locations. (Stamford Advocate)

    Fairfield County scene: Castaways gala  Jul 9, 2007
    Triathlon Darien Sport Shop and the ITP (Idiopathic Thrombocytopenic Purpura) Foundation of Darien present the third annual triathlon to raise funds for ITP research. Triathlons will be held in Darien and New Canaan; see Web site for locations. (Greenwich Time)

    Thrombocytopenia  Jul 1, 2007
    Immense blood transfusions can weaken platelet concentration in the blood Idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura, and hemolytic- uremic syndrome (body can use or destroy too many platelets) (1). What drugs are associated with the development of thrombocytopenia and how is thrombocytopenia treated in individuals. (Suite101.com)

    Fairfield County Scene  Jun 18, 2007
    Triathlon Darien Sport Shop and the ITP (Idiopathic Thrombocytopenic Purpura) Foundation of Darien presents the third annual triathlon for athletes to swim 0. 5 miles, bicycle 5 miles and run 5 miles in succession to raise funds for ITP research. (Stamford Advocate)

    GlaxoSmithKline Cites Promacta Results  Jun 12, 2007
    The treatment is aimed at patients with idiopathic thrombocytopenic purpura, a bleeding disorder where blood does not clot properly. Patients with the condition have a low platelet count. (Forbes)

    Autoimmune Neutropenia  Jun 6, 2007
    Similar to the platelet deficiency idiopathic thrombocytopenic purpura, vaccines are suspected of triggering this disorder. Treatment. (Suite101.com)

    Multiple Autoimmune Syndrome  Apr 11, 2007
    Type 3 MAS groups together autoimmune thyroid disease, myasthenia gravis and/or thymoma, Sjogren s syndrome, , idiopathic thrombocytopenic purpura (ITP), , insulin dependent diabetes, vitiligo,, systemic lupus erythematosus (SLE), and dermatitis herpetiformis. For this group, the immune system marker HLA-B8 and/or DR3 or DR5 seems to be an important factor. (Suite101.com)

    Clinical Trials Update: March 22, 2007  Mar 23, 2007
    Thrombocytopenia and Thrombocytopenia Prevention (Health-Finder)

    JEFFERSON AWARDPresented to Mark and Bonnie Barnes  Feb 12, 2007
    JEFFERSON AWARD / Presented to Mark and Bonnie Barnes / Group salutes soothing skills, spirits of nurses. "Even when Pat was totally sedated, they were amazing. We wanted to find a way to go around the country and say thank you to nurses for the kind of care they give people every day. "With ITP, your body creates antibodies that attack your platelets. (San Francisco Chronicle)

    Online tool helps physicians improve care of patients with bleeding disorder  Feb 8, 2007
    (WASHINGTON and PHILADELPHIA, February 7, 2007) Physicians who treat a blood disorder called idiopathic thrombocytopenic purpura (ITP), characterized by easy bruising and excessive bleeding, now have a new tool to help them provide the best care for patients with this disease. This Web-based performance evaluation tool is the first non-malignant hematology Practice Improvement Module (PIM), co-created by the American Society of Hematology (ASHTM) and the American Board of Internal Medicine... (EurekAlert! -- Business News)

    Discovery May Lead To Novel Treatments For Autoimmune And Chronic Inflammatory Diseases  Jan 30, 2007
    For years, doctors have used IVIG to treat patients with autoimmune and chronic inflammatory diseases, such as dermatomyositis, Kawasaki disease, multiple sclerosis, lupus, chronic lymphocytic leukemia, and idiopathic thrombocytopenic purpura, but just how the therapy works has remained a mystery. Some researchers have shown that IVIG works, in part, by activating a receptor known as Fc3RIIb, which then suppresses auto-antibody-mediated inflammation. (Science Daily)



    Back to Health News

[ Terms Of Use | Privacy | About ]
©1998-2008 SurfWax, Inc.
All rights reserved. Patents pending.



Copyright SurfWax, Inc. 2008